Project Grant R35GM165302
- The National Institute of General Medical Sciences awarded the University of Florida $386,985 on July 23, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct a five-year investigation into the structure-function relationships of single-stranded DNA (ssDNA) in biological systems. The research will develop methods to probe structured ssDNA in cells, with initial focus on two biomedically relevant lines of investigation. The first examines complex ssDNA...
- The National Institute of General Medical Sciences awarded the University of Florida $322,252 on August 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to discover and characterize small molecule inhibitors of bacterial ribonuclease P (RNase P), a tRNA processing enzyme. Work is performed in Gainesville, Florida through April 30, 2030. The project integrates structural biology, biochemistry, and computation to develop small molecule inhibitors targeting RNase...
- The National Institute of General Medical Sciences awarded the University of Florida $398,545 on September 3, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate how active and silenced transposable elements shape meiotic recombination in maize and rice. The research will generate high-resolution crossover maps and perform genome-wide assessment of recombination frequency near transposon insertions, examine whether transposon-derived double-strand...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Florida $111,342 on December 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research elucidating the antiviral mechanisms of OAS family innate immune sensors. The award funds investigation into how oligoadenylate synthetase (OAS) proteins recognize viral RNA and activate innate immune responses to restrict viral...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Florida $454,738 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how cytosolic pattern recognition receptors sense membrane-replicating positive-strand RNA viruses despite viral replication sequestering viral RNA from host cell cytoplasmic sensors. The research addresses a fundamental paradox in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $750,263 on June 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacteriophage predation influences diarrheal disease severity and antimicrobial resistance emergence. The research uses cholera as a model system to validate findings in a new patient cohort and tests underlying theory across high-priority enteric pathogens including Shigella species and...
- The National Institute of General Medical Sciences, National Institutes of Health, awarded the University of Florida $422,125 on August 15, 2026, to develop rapid, wash-free fluorescent signal-switching methods for high-plex RNA imaging in cells and tissues under the Biomedical Research and Research Training program (CFDA 93.859). The research addresses limitations in current multiplexed fluorescence imaging by establishing a DNA displacement reaction-based signal exchange (DIRSE) platform...
- The National Institute of General Medical Sciences awarded the University of Florida $411,407 on August 15, 2026, to develop a bioanalytical platform for monitoring and modeling sepsis immunopathology under the Biomedical Research and Research Training program (CFDA 93.859). The funded research establishes an integrated platform to capture ultrasensitive, longitudinal biochemical monitoring of immune effectors in sepsis patients and develop dynamic disease models linking biochemical trends to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $219,532 on August 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a noncanonical STING-dependent, interferon-I-independent antiviral pathway against Kaposi's sarcoma-associated herpesvirus reactivation. The project addresses mechanisms by which the STING pathway restricts KSHV reactivation despite the virus's ability to suppress type I interferon...
- The National Institute of General Medical Sciences awarded the University of Florida $383,750 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct basic research on post-translational modification systems in archaea, with performance through January 31, 2031, at Gainesville, Florida. The project advances understanding of how post-translational modifications coordinate to regulate stress response in the archaeon Haloferax volcanii. Three...
The National Institute of General Medical Sciences awarded the University of Florida $422,125 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the molecular mechanisms of schlafen-mediated phage defense. The award funds two projects examining how schlafen nucleases function as an ancient antiviral defense mechanism. Project 1 determines the molecular, structural, and biochemical basis of schlafen immunity in bacterial systems. Project 2 investigates the biological consequences of tRNA cleavage on host cell physiology and infection outcomes. The research establishes mechanistic parallels between prokaryotic and eukaryotic antiviral defenses, examining how bacterial schlafens sense infection, activate immune responses, and restrict bacteriophage replication through tRNA cleavage and translational arrest. The work contributes to fundamental understanding of RNA-targeting antiviral mechanisms and may inform development of molecular tools with applications in science and medicine. The University of Florida's Division of Sponsored Research is the recipient. Work is performed in Gainesville, Florida, with a period of performance extending from September 1, 2026, through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $422.1k | 8/18/26 |